E
Eliaz Therapeutics Inc
Profile managed by Bizz IdEliaz Therapeutics
Estados Unidos
1-10 employees
2015
Description
Biopharmaceutical company founded in 2015 developing the XGal-3® apheresis device, first-in-class to selectively remove Galectin-3 from the blood. Applications in cancer, sepsis, fibrosis and kidney disease. Received FDA Breakthrough Device designation.